---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-306251"
form_type: "8-K/A"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2026-07-16T21:20:16+00:00"
generated_at: "2026-07-16T21:22:05.282506+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics discloses separation agreement with former executive Craig Tooman

## Summary
- Salary continuation of $655,000 for 12 months plus lump sum cash severance of $250,000.
- Bonus payment of $283,746.03 and healthcare premium reimbursement of $46,896.48.
- Extended option exercise period: 24 months for 2023 Plan options, 12 months for 2018 Plan options.
- Acceleration of unvested options upon change of control within 12 months post-separation.
- Confidentiality, non-disparagement, non-solicitation covenants and release of claims.

## SEC filing metadata
- accession: 0001193125-26-306251
- form_type: 8-K/A
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2026-07-16T21:20:16+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312526306251/0001193125-26-306251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312526306251/sln-20260710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-306251
- JSON: https://secwatch.observer/filing/0001193125-26-306251.json
- Plain text: https://secwatch.observer/filing/0001193125-26-306251.txt

## Key facts
- Executive change
  Craig Tooman resigned as other_named_officer at Silence Therapeutics plc.
  - Action: resigned
  source text: As reported in the Original Form 8-K, effective as of December 14, 2025 (the “Separation Date”), Craig Tooman agreed by mutual consent to end his employment with Silence Therapeutics plc (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526306251/0001193125-26-306251-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.